{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:01:30Z","timestamp":1792512090560,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:00:00Z","timestamp":1446681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1857-x","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T22:35:54Z","timestamp":1446676554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma \u2013 a Swedish population-based study"],"prefix":"10.1186","volume":"15","author":[{"given":"Mohammad","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bottai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"issue":"4","key":"1857_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA Cancer J Clin. 2011;61(4):212\u201336. doi: 10.3322\/caac.20121 .","journal-title":"CA Cancer J Clin"},{"key":"1857_CR2","unstructured":"GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. [database on the Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx , accessed: on 12\/06\/2014."},{"issue":"3","key":"1857_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.emc.2014.04.004","volume":"32","author":"H Rose-Inman","year":"2014","unstructured":"Rose-Inman H, Kuehl D. Acute leukemia. Emerg Med Clin North Am. 2014;32(3):579\u201396. doi: 10.1016\/j.emc.2014.04.004 .","journal-title":"Emerg Med Clin North Am"},{"issue":"3","key":"1857_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.juro.2010.10.061","volume":"185","author":"A Berglund","year":"2011","unstructured":"Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185(3):833\u20139. doi: 10.1016\/j.juro.2010.10.061 .","journal-title":"J Urol"},{"issue":"7","key":"1857_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/bjc.2012.46","volume":"106","author":"TL Jorgensen","year":"2012","unstructured":"Jorgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106(7):1353\u201360. doi: 10.1038\/bjc.2012.46 .","journal-title":"Br J Cancer"},{"issue":"2","key":"1857_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.critrevonc.2011.03.001","volume":"81","author":"LH Land","year":"2012","unstructured":"Land LH, Dalton SO, Jorgensen TL, Ewertz M. Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol Hematol. 2012;81(2):196\u2013205. doi: 10.1016\/j.critrevonc.2011.03.001 .","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"1857_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00432-010-0973-x","volume":"137","author":"Y Kobayashi","year":"2011","unstructured":"Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D, et al. Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2011;137(7):1079\u201384. doi: 10.1007\/s00432-010-0973-x .","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"1857_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/bmt.2010.188","volume":"46","author":"WJ Plattel","year":"2011","unstructured":"Plattel WJ, Kluin-Nelemans HC, de Bock GH, van Imhoff GW. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2011;46(6):827\u201334. doi: 10.1038\/bmt.2010.188 .","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1857_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2141.2005.05508.x","volume":"129","author":"ML Janssen-Heijnen","year":"2005","unstructured":"Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, Houterman S, Verheij KD, Coebergh JW. A population-based study of severity of comorbidity among patients with non-Hodgkin\u2019s lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol. 2005;129(5):597\u2013606. doi: 10.1111\/j.1365-2141.2005.05508.x .","journal-title":"Br J Haematol"},{"issue":"11","key":"1857_CR10","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2008.197","volume":"22","author":"A Xhaard","year":"2008","unstructured":"Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia. 2008;22(11):2062\u20139. doi: 10.1038\/leu.2008.197 .","journal-title":"Leukemia"},{"issue":"3","key":"1857_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/hon.889","volume":"27","author":"M Breccia","year":"2009","unstructured":"Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol. 2009;27(3):148\u201353. doi: 10.1002\/hon.889 .","journal-title":"Hematol Oncol"},{"issue":"2","key":"1857_CR12","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s12032-011-9853-8","volume":"29","author":"I Djunic","year":"2012","unstructured":"Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, et al. Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. Med Oncol. 2012;29(2):1077\u201381. doi: 10.1007\/s12032-011-9853-8 .","journal-title":"Med Oncol"},{"issue":"7","key":"1857_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22537","volume":"109","author":"A Etienne","year":"2007","unstructured":"Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, Coso D, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007;109(7):1376\u201383. doi: 10.1002\/cncr.22537 .","journal-title":"Cancer"},{"issue":"3","key":"1857_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/leu.2014.234","volume":"29","author":"LS Ostgard","year":"2014","unstructured":"Ostgard LS, Norgaard JM, Sengelov H, Severinsen M, Friis LS, Marcher CW, et al. Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia. 2014;29(3):548\u201355. doi: 10.1038\/leu.2014.234 .","journal-title":"Leukemia"},{"issue":"6","key":"1857_CR15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/leu.2009.1","volume":"23","author":"L Farina","year":"2009","unstructured":"Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009;23(6):1131\u20138. doi: 10.1038\/leu.2009.1 .","journal-title":"Leukemia"},{"issue":"6","key":"1857_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2012-03-414573","volume":"120","author":"R Raimondi","year":"2012","unstructured":"Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A, et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood. 2012;120(6):1327\u201333. doi: 10.1182\/blood-2012-03-414573 .","journal-title":"Blood"},{"issue":"4","key":"1857_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/bmt.2011.138","volume":"47","author":"SW Bokhari","year":"2012","unstructured":"Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant. 2012;47(4):528\u201334. doi: 10.1038\/bmt.2011.138 .","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"1857_CR18","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1200\/JCO.2008.18.2006","volume":"27","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY, Derolf AR, Edgren G, Dickman PW, Bjorkholm M. Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden. J Clin Oncol. 2009;27(12):2073\u201380. doi: 10.1200\/jco.2008.18.2006 .","journal-title":"J Clin Oncol"},{"issue":"5","key":"1857_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"11","key":"1857_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"1","key":"1857_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27\u201333. doi: 10.1080\/02841860802247664 .","journal-title":"Acta Oncol"},{"key":"1857_CR22","unstructured":"Socialstyrelsen. The national board of health and welfare, Sweden. Available from: https:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/cancerregistret\/inenglish . Accessed: 12\/06\/2014"},{"key":"1857_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi: 10.1186\/1471-2458-11-450 .","journal-title":"BMC Public Health"},{"issue":"5","key":"1857_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/ard.60.5.433","volume":"60","author":"M Abu-Shakra","year":"2001","unstructured":"Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis. 2001;60(5):433\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1857_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s10067-011-1799-x","volume":"30","author":"V Ravindran","year":"2011","unstructured":"Ravindran V, Anoop P. Rheumatologic manifestations of benign and malignant haematological disorders. Clin Rheumatol. 2011;30(9):1143\u20139. doi: 10.1007\/s10067-011-1799-x .","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1857_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","volume":"53","author":"LM Knudsen","year":"1994","unstructured":"Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207\u201312.","journal-title":"Eur J Haematol"},{"key":"1857_CR27","unstructured":"Statistics Sweden. Background Facts, Labour and Education Statistics 2009:1, Integrated database for labour market research. Statistics Sweden, Sweden 2009."},{"issue":"6","key":"1857_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2105\/AJPH.82.6.816","volume":"82","author":"MA Winkleby","year":"1992","unstructured":"Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am J Public Health. 1992;82(6):816\u201320.","journal-title":"Am J Public Health"},{"key":"1857_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/oxfordjournals.epirev.a036030","volume":"10","author":"P Liberatos","year":"1988","unstructured":"Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. Epidemiol Rev. 1988;10:87\u2013121.","journal-title":"Epidemiol Rev"},{"issue":"3","key":"1857_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ije\/29.3.495","volume":"29","author":"LA Johansson","year":"2000","unstructured":"Johansson LA, Westerling R. Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol. 2000;29(3):495\u2013502.","journal-title":"Int J Epidemiol"},{"issue":"20","key":"1857_CR31","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/jnci\/djq366","volume":"102","author":"N Howlader","year":"2010","unstructured":"Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102(20):1584\u201398. doi: 10.1093\/jnci\/djq366 .","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1857_CR32","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jclinepi.2009.01.010","volume":"62","author":"LA Johansson","year":"2009","unstructured":"Johansson LA, Bjorkenstam C, Westerling R. Unexplained differences between hospital and mortality data indicated mistakes in death certification: an investigation of 1,094 deaths in Sweden during 1995. J Clin Epidemiol. 2009;62(11):1202\u20139. doi: 10.1016\/j.jclinepi.2009.01.010 .","journal-title":"J Clin Epidemiol"},{"key":"1857_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-13-13","volume":"13","author":"SR Hinchliffe","year":"2013","unstructured":"Hinchliffe SR, Lambert PC. Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. BMC Med Res Methodol. 2013;13:13. doi: 10.1186\/1471-2288-13-13 .","journal-title":"BMC Med Res Methodol"},{"issue":"18","key":"1857_CR34","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179\u201387. doi: 10.1182\/blood-2008-07-172007 .","journal-title":"Blood"},{"issue":"9","key":"1857_CR35","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481\u20135. doi: 10.1182\/blood-2005-09-3724 .","journal-title":"Blood"},{"issue":"10","key":"1857_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.leukres.2014.06.020","volume":"38","author":"M Breccia","year":"2014","unstructured":"Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, et al. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk Res. 2014;38(10):1173\u20136. doi: 10.1016\/j.leukres.2014.06.020 .","journal-title":"Leuk Res"},{"issue":"12","key":"1857_CR37","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","volume":"97","author":"B Oran","year":"2012","unstructured":"Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916\u201324. doi: 10.3324\/haematol.2012.066100 .","journal-title":"Haematologica"},{"issue":"8","key":"1857_CR38","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3109\/10428194.2014.985672","volume":"56","author":"BK Budziszewska","year":"2014","unstructured":"Budziszewska BK, Pluta A, Sulek K, Wierzbowska A, Robak T, Giebel S, et al. Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities; a Polish Adult Leukemia Group (PALG) study. Leuk Lymphoma. 2014;56(8):2331\u20138. doi: 10.3109\/10428194.2014.985672 .","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"1857_CR39","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18):2514\u201320. doi: 10.1200\/jco.2011.34.7146 .","journal-title":"J Clin Oncol"},{"issue":"7","key":"1857_CR40","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122(7):1284\u201392. doi: 10.1182\/blood-2013-04-495598 .","journal-title":"Blood"},{"issue":"7","key":"1857_CR41","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3109\/10428194.2014.993391","volume":"56","author":"M Breccia","year":"2014","unstructured":"Breccia M, Molica M, Colafigli G, Zacheo I, Latagliata R, Tafuri A, et al. Correlation between Charlson comorbidity index and outcome in chronic phase chronic myeloid leukemia patients treated with second generation tkis upfront. Leuk Lymphoma. 2014;56(7):2206\u20137. doi: 10.3109\/10428194.2014.993391 .","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1857_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2013.11.002","volume":"25","author":"A Iurlo","year":"2014","unstructured":"Iurlo A, Ubertis A, Artuso S, Bucelli C, Radice T, Zappa M, et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med. 2014;25(1):63\u20136. doi: 10.1016\/j.ejim.2013.11.002 .","journal-title":"Eur J Intern Med"},{"issue":"9","key":"1857_CR43","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","volume":"22","author":"MS Marcolino","year":"2011","unstructured":"Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22(9):2073\u20139. doi: 10.1093\/annonc\/mdq715 .","journal-title":"Ann Oncol"},{"issue":"8","key":"1857_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40266-013-0088-6","volume":"30","author":"R Latagliata","year":"2013","unstructured":"Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, et al. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging. 2013;30(8):629\u201337. doi: 10.1007\/s40266-013-0088-6 .","journal-title":"Drugs Aging"},{"issue":"10","key":"1857_CR45","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","volume":"96","author":"M Breccia","year":"2011","unstructured":"Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011;96(10):1457\u201361. doi: 10.3324\/haematol.2011.041251 .","journal-title":"Haematologica"},{"key":"1857_CR46","doi-asserted-by":"publisher","unstructured":"Klepin HD, Rizzieri D, Palumbo A, Magarotto V, Eichhorst B. Individualizing treatment decisions for older adults with hematologic malignancies. American Society of Clinical Oncology educational book \/ ASCO American Society of Clinical Oncology Meeting. 2013:208\u201319. doi: 10.1200\/EdBook_AM.2013.33.208 .","DOI":"10.1200\/EdBook_AM.2013.33.208"},{"issue":"15","key":"1857_CR47","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","volume":"25","author":"SY Kristinsson","year":"2007","unstructured":"Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993\u20139. doi: 10.1200\/jco.2006.09.0100 .","journal-title":"J Clin Oncol"},{"issue":"8","key":"1857_CR48","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","volume":"19","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Sonneveld P, Davies F, Blade J, Boccadoro M, Cavo M, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19(8):829\u201344. doi: 10.1634\/theoncologist.2014-0042 .","journal-title":"Oncologist"},{"issue":"5","key":"1857_CR49","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","volume":"13","author":"M Kleber","year":"2013","unstructured":"Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wasch R, et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013;13(5):541\u201351. doi: 10.1016\/j.clml.2013.03.013 .","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"1857_CR50","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/bcj.2011.34","volume":"1","author":"M Kleber","year":"2011","unstructured":"Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood cancer J. 2011;1(9):e35. doi: 10.1038\/bcj.2011.34 .","journal-title":"Blood cancer J"},{"issue":"2","key":"1857_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48(2):337\u201341. doi: 10.1080\/10428190601126602 .","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1857_CR52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jclinepi.2013.11.012","volume":"67","author":"D Sarfati","year":"2014","unstructured":"Sarfati D, Gurney J, Stanley J, Salmond C, Crampton P, Dennett E, et al. Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices. J Clin Epidemiol. 2014;67(5):586\u201395. doi: 10.1016\/j.jclinepi.2013.11.012 .","journal-title":"J Clin Epidemiol"},{"key":"1857_CR53","doi-asserted-by":"publisher","unstructured":"Palumbo A, Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology \/ the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2009:566\u201377. doi: 10.1182\/asheducation-2009.1.566 .","DOI":"10.1182\/asheducation-2009.1.566"},{"issue":"3","key":"1857_CR54","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10552-012-0141-5","volume":"24","author":"S Eloranta","year":"2013","unstructured":"Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TM, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24(3):505\u201315. doi: 10.1007\/s10552-012-0141-5 .","journal-title":"Cancer Causes Control"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1857-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1857-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1857-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T18:57:05Z","timestamp":1498244225000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1857-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1857-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,5]]},"article-number":"850"}}